ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1

Lymphocyte Proliferation to a Cross-Reactive Gut Commensal Candidate in Antiphospholipid Syndrome

William Ruff1, Silvio M. Vieira2, Cassyanne Aguiar3,4, John Sterpka2, Andrew Goodman5, Doruk Erkan3,6 and Martin Kriegel1,7, 1Immunobiology, Yale School of Medicine, New Haven, CT, 2Yale School of Medicine, New Haven, CT, 3New York Presbyterian/Weill Cornell Medical Center, New York, NY, 4Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, 5Microbial Pathogenesis, Yale School of Medicine, Microbial Diversity Institute, New Haven, CT, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: antiphospholipid syndrome, Auto-immunity, autoantigens and microbiome, Mimickers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Antiphospholipid Syndrome

Session Type: Abstract Submissions (ACR)

Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune clotting disorder of unknown etiology targeting a major autoantigen, β2-glycoprotein I (β2GPI). Infectious triggers have been implicated in transient autoantibody production, but the persistent stimuli for anti-β2GPI antibodies remain unknown. Given the vast antigenic potential of the gut microbiota, we hypothesize that human gut commensal bacteria induce and sustain autoreactivity via cross-reactivity. To this end, we characterized APS PBMC reactivity to in silico candidates and determined fecal autoantibody production.

Methods: Protein BLAST and Clustal Omega were used to identify commensal protein sequences with high homology to β2GPI-dominant epitopes. Using anaerobic cultures, we grew isolated candidate and control strains. Blood and stool samples were obtained from anti-β2GPI-positive patients, non-autoimmune thrombophilia patients, and healthy controls. Stool DNA was isolated using the MoBio extraction kit. A novel species-specific real-time PCR strategy was developed and validated using isolated strains and defined fecal microbiomes. In vitro proliferation of PBMC to bacterial protein extracts was assessed by [3H]-thymidine incorporation. An in-house ELISA was established with high-binding plates to analyze anti-β2GPI levels in plasma and fecal supernatants.

Results: Systematic in silico searches revealed Roseburia intestinalis as a major candidate for cross-reactivity. R. intestinalis is a common colonic gram-positive, flagellated, mucus adhering commensal containing high homology to the main B and T cell epitopes of β2GPI. R. intestinalis colonization load was semi-quantified in patients and controls using real-time PCR. APS PBMC proliferated significantly more to protein extracts from R. intestinalis versus control subjects (n=5-6; p=0.0002), and also compared to the closely phylogenetically related, but mimic-deficient gut commensal Eubacterium rectale (n=6, p=0.020). Importantly, we were also able to detect anti-β2GPI IgA antibodies in APS fecal supernatants, which differed significantly compared to controls (n=14-15; p=0.0019).

Conclusion: We have identified a major cross-reactive commensal candidate in silico with high homology to dominant β2GPI epitopes and developed a highly specific real-time PCR-based screening strategy. APS PBMCs proliferated significantly more to candidate protein extracts compared to controls. Furthermore, we report, to our knowledge, for the first time fecal autoantibody production in a non-gut autoimmune disease. Production of fecal anti-β2GPI IgA in patients with peripheral blood anti-β2GPI IgG supports our hypothesis of a gut mucosal, cross-reactive trigger in APS, which we are actively pursuing.


Disclosure:

W. Ruff,
None;

S. M. Vieira,
None;

C. Aguiar,
None;

J. Sterpka,
None;

A. Goodman,
None;

D. Erkan,
None;

M. Kriegel,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lymphocyte-proliferation-to-a-cross-reactive-gut-commensal-candidate-in-antiphospholipid-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology